Denali Therapeutics Inc. (DNLI) Tops Q4 EPS by 17c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.67), $0.17 better than the analyst estimate of ($0.84).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Take-Two Interactive Software: GTA VI launches November 19, 2026 for PS5 and Xbox series X|S at $79.99
• Barclays Starts SAB Biotherapeutics (SABS) at Overweight